Literature DB >> 17570524

A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients.

Raphael P M Curvo, Ilana R Zalcberg, Vanesa Scholl, Virginia Pires, Arthur Moellmann-Coelho, Miguel A M Moreira.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17570524     DOI： 10.1016/j.leukres.2007.04.018

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  5 in total

1.  Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia.

Authors:  Nóra Meggyesi; Lajos Kalmár; Sándor Fekete; Tamás Masszi; Attila Tordai; Hajnalka Andrikovics
Journal:  Med Oncol       Date:  2011-10-30       Impact factor: 3.064

2.  BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?

Authors:  Franz X Gruber; Tuija Lundán; Rasmus Goll; Aleksandra Silye; Ingvild Mikkola; Ole Petter Rekvig; Sakari Knuutila; Kari Remes; Tobias Gedde-Dahl; Kimmo Porkka; Henrik Hjorth-Hansen
Journal:  Med Oncol       Date:  2011-01-08       Impact factor: 3.064

3.  [Discovery of a novel spliceosome of ABL gene (ABL(Δexon7+35INS)) and its association with TKIs resistance in chronic myeloid leukemia].

Authors:  J Pan; Y H Tan; J X Zhao; X H Chen; Z F Xu; J Xu; J M Chang; F Xue; N Zhang; F G Ren; Y F Zhang; X J Wang; H W Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2016-06-14

4.  Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing.

Authors:  R Kastner; A Zopf; S Preuner; J Pröll; N Niklas; P Foskett; P Valent; T Lion; C Gabriel
Journal:  Eur J Cancer       Date:  2013-12-20       Impact factor: 9.162

5.  BCR-ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia and TKI resistance.

Authors:  Irina Nemchenko; Olga Nesterova; Ilya Mikhailov; Andrey Sudarikov
Journal:  Clin Case Rep       Date:  2018-09-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.